Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers

References

• American Society of Clinical Oncology. Lung cancer – small cell: statistics [cited 2021 Jul 1]. Available from: https://www.cancer.net/cancer-types/lung-cancer-small-cell/statistics
   Google Scholar
• American Society of Clinical Oncology. Lung cancer – small cell: stages [cited 2021 Jul 1]. Available from: https://www.cancer.net/cancer-types/lung-cancer-small-cell/stages
   Google Scholar
• National Comprehensive Cancer Network. Small cell lung cancer (version 3.2021); 2021 [cited 2021 Jul 1]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
   Google Scholar
• Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS Meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692–1698.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229.
   PubMed Web of Science ®Google Scholar
• Tecentriq. Prescribing information; 2021 [cited 2021 Jul 1]. Available from: https://www.gene.com/download/pdf/tecentriq_prescribing.pdf
   Google Scholar
• Imfinzi. Prescribing information; 2021 [cited 2021 Jul 1]. Available from: https://www.azpicentral.com/imfinzi/imfinzi.pdf#page=1
   Google Scholar
• US Food and Drug Administration. FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer; 2020 [cited 2021 Jul 1]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer
   Google Scholar
• Carey PJ. Drug-induced myelosuppression : diagnosis and management. Drug Saf. 2003;26(10):691–706.
   PubMed Web of Science ®Google Scholar
• Bryer E, Henry D. Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice. IJCTM. 2018;6:21–31.
   Google Scholar
• Corey-Lisle PK, Desrosiers MP, Collins H, et al. Transfusions and patient burden in chemotherapy-induced anaemia in France. Ther Adv Med Oncol. 2014;6(4):146–153.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology. 2015;29(4):282–294.
   PubMed Web of Science ®Google Scholar
• Weycker D, Hatfield M, Grossman A, et al. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer. 2019;19(1):151.
   PubMedGoogle Scholar
• Lalami Y, Klastersky J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol. 2017;120:163–179.
   PubMed Web of Science ®Google Scholar
• Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol. 2010;28(26):4086–4093.
   PubMed Web of Science ®Google Scholar
• Extermann M. Interaction between comorbidity and cancer. Cancer Control. 2007;14(1):13–22.
   PubMedGoogle Scholar
• Bohlius J, Bohlke K, Lazo-Langner A. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. JOP. 2019;15(7):399–402.
   Google Scholar
• Aapro M, Ludwig H, Bokemeyer C, et al. Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). Ann Oncol. 2016;27(11):2039–2045.
   PubMed Web of Science ®Google Scholar
• Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205–213.
   PubMed Web of Science ®Google Scholar
• Lyman GH. Issues on the use of white blood cell growth factors in oncology practice. Am Soc Clin Oncol Educ Book. 2016; 35:e528–e532.
   PubMedGoogle Scholar
• Liou SY, Stephens JM, Carpiuc KT, et al. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig. 2007;27(6):381–396.
   PubMed Web of Science ®Google Scholar
• Tai E, Guy GP, Dunbar A, et al. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. JOP. 2017;13(6):e552–e561.
   PubMedGoogle Scholar
• Wong W, Yim YM, Kim A, et al. Assessment of costs associated with adverse events in patients with cancer. PLoS One. 2018;13(4):e0196007.
   PubMed Web of Science ®Google Scholar
• Association of Community Cancer Centers; 2021 [cited 2021 Jun 8]. Available from: https://www.accc-cancer.org/home/about
   Google Scholar
• Community Oncology Alliance. FACT Sheet: What is community oncology? 2017 [cited 2021 Jun 8]. Available from: https://communityoncology.org/wp-content/uploads/2017/08/What-is-Comm-Onc.pdf
   Google Scholar
• Kirkwood MK, Hanley A, Bruinooge SS, et al. The state of oncology practice in America, 2018: results of the ASCO practice census Survey. J Oncol Pract. 2018;14(7):e412–e420.
   PubMed Web of Science ®Google Scholar
• Providence. 2021 [cited 2021 Jun 8]. Available from: https://www.providence.org/locations/st-joseph-hospital-orange/about-us
   Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0; 2017 [cited 2021 Jul 1]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
   Google Scholar
• Jalal SI, Lavin P, Lo G, et al. Carboplatin and etoposide with or without palifosfamide in untreated extensive-stage small-cell lung cancer: a multicenter, adaptive, randomized phase III study (MATISSE). J Clin Oncol. 2017;35(23):2619–2623.
   PubMed Web of Science ®Google Scholar
• Sun Y, Cheng Y, Hao X, et al. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. BMC Cancer. 2016;16:265.
   PubMed Web of Science ®Google Scholar
• Tiseo M, Boni L, Ambrosio F, et al. Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol. 2017;35(12):1281–1287.
   PubMed Web of Science ®Google Scholar
• Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21(9):1810–1816.
   PubMed Web of Science ®Google Scholar
• Hanna N, Bunn PA, Jr., Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24(13):2038–2043.
   PubMed Web of Science ®Google Scholar
• Igawa S, Shirasawa M, Ozawa T, et al. Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status. Thorac Cancer. 2018;9(8):967–973.
   PubMed Web of Science ®Google Scholar
• Yilmaz U, Polat G, Anar C, et al. Carboplatin plus etoposide for extensive stage small-cell lung cancer: an experience with AUC 6 doses of carboplatin. Indian J Cancer. 2011;48(4):454–459.
   PubMed Web of Science ®Google Scholar
• Crawford J, Kosmidis PA, Hirsch FR, et al. Targeting anemia in patients with lung cancer. J Thorac Oncol. 2006;1(7):716–725.
   PubMed Web of Science ®Google Scholar
• Barney CL, Scoville N, Allan E, et al. Radiation dose to the thoracic vertebral bodies is associated with acute hematologic toxicities in patients receiving concurrent chemoradiation for lung cancer: results of a single-center retrospective analysis. Int J Radiat Oncol Biol Phys. 2018;100(3):748–755.
   PubMed Web of Science ®Google Scholar
• Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–1125.
   PubMed Web of Science ®Google Scholar
• Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019;30(10):1613–1621.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Hematopoietic growth factors (version 1.2021); 2021 [cited 2021 Mar 2]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf
   Google Scholar
• Chouaid C, Bassinet L, Fuhrman C, et al. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol. 1998;16(8):2700–2707.
   PubMed Web of Science ®Google Scholar
• Adams JR, Lyman GH, Djubegovic B, et al. G-CSF as prophylaxis of febrile neutropenia in SCLC. Expert Opin Pharmacother. 2002;3(9):1273–1281.
   PubMedGoogle Scholar
• Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006;24(19):2991–2997.
   PubMed Web of Science ®Google Scholar
• Ramsey SD, McCune JS, Blough DK, et al. Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am J Manag Care. 2010;16(9):678–686.
   PubMed Web of Science ®Google Scholar
• Wright JD, Neugut AI, Ananth CV, et al. Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med. 2013;173(7):559–568.
   PubMed Web of Science ®Google Scholar
• Gascón P, Aapro M, Ludwig H, et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer. 2016;24(2):911–825.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Gascón P, Aapro M, et al. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study. Support Care Cancer. 2017;25(6):1819–1828.
   PubMed Web of Science ®Google Scholar
• Pelayo Alvarez M, Westeel V, Cortés-Jofré M, et al. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev. 2013;(11):CD001990.
   PubMed Web of Science ®Google Scholar
• Chan BA, Coward JI. Chemotherapy advances in small-cell lung cancer. J Thorac Dis. 2013;5:S565–S578.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939.
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24(34):5441–5447.
   PubMed Web of Science ®Google Scholar
• Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25(15):2086–2092.
   PubMed Web of Science ®Google Scholar
• von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658–667.
   PubMed Web of Science ®Google Scholar
• Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008;26(26):4261–4267.
   PubMed Web of Science ®Google Scholar
• Crawford J, Denduluri N, Patt D, et al. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Support Care Cancer. 2020;28(2):925–932.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116(23):5555–5563.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Kuderer NM, Aapro M. Improving outcomes of chemotherapy: established and novel options for myeloprotection in the COVID-19 era. Front Oncol. 2021;11:697908.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. COSELA™ Prescribing Information; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf
   Google Scholar
• Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial. Int J Cancer. 2021;148(10):2557–2570.
   PubMed Web of Science ®Google Scholar
• Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: Results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther. 2021;38(1):350–365.
   PubMed Web of Science ®Google Scholar